Karuna quintuples in value as schizophrenia combo clears Phase II bar

Karuna added about $1.8 billion in market cap Monday after a Phase II trial showed its combo therapy targeting muscarinic receptors led to significantly lower psychosis scores in patients with schizophrenia while avoiding the side effects that dogged a decades-old attempt to modulate the targets.

Shares of Karuna Therapeutics Inc.

Read the full 491 word article

How to gain access

Continue reading with a
two-week free trial.